PepGen (PEPG) Expected to Announce Earnings on Monday

PepGen (NASDAQ:PEPG) will likely be releasing its Q4 2025 results before the market opens on Monday, February 23rd. Analysts expect PepGen to post earnings of ($0.38) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 26, 2026 at 9:30 AM ET.

PepGen Price Performance

Shares of PepGen stock opened at $6.44 on Monday. The firm has a market cap of $442.75 million, a price-to-earnings ratio of -2.28 and a beta of 1.91. The stock’s 50-day moving average is $5.68 and its 200-day moving average is $4.24. PepGen has a one year low of $0.88 and a one year high of $7.80.

Wall Street Analyst Weigh In

PEPG has been the topic of several recent research reports. HC Wainwright lifted their price target on shares of PepGen from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Wall Street Zen raised shares of PepGen from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of PepGen in a report on Thursday, January 22nd. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $11.75.

Institutional Trading of PepGen

Hedge funds have recently added to or reduced their stakes in the stock. Rangeley Capital LLC grew its holdings in shares of PepGen by 133.3% during the second quarter. Rangeley Capital LLC now owns 35,000 shares of the company’s stock worth $39,000 after purchasing an additional 20,000 shares during the last quarter. Marshall Wace LLP acquired a new stake in PepGen during the 2nd quarter worth approximately $44,000. Burkehill Global Management LP bought a new stake in PepGen during the 3rd quarter worth approximately $46,000. Militia Capital Partners LP acquired a new position in PepGen in the 3rd quarter valued at approximately $72,000. Finally, Qube Research & Technologies Ltd bought a new position in shares of PepGen during the second quarter valued at $81,000. Institutional investors and hedge funds own 58.01% of the company’s stock.

About PepGen

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).